The Mediterranean Diet, its Components, and Cardiovascular Disease

R. Jay Widmer, MD, PhD,a Andreas J. Flammer, MD,a Lilach O. Lerman, MD, PhD,b Amir Lerman, MDa

Division of Cardiovascular Diseases andb Division of Nephrology and Hypertension, Mayo School of Graduate Medical Education, Rochester, Minn.

ABSTRACT

One of the best-studied diets for cardiovascular health is the Mediterranean diet. This consists of fish, monounsaturated fats from olive oil, fruits, vegetables, whole grains, legumes/nuts, and moderate alcohol consumption. The Mediterranean diet has been shown to reduce the burden, or even prevent the development, of cardiovascular disease, breast cancer, depression, colorectal cancer, diabetes, obesity, asthma, erectile dysfunction, and cognitive decline. This diet is also known to improve surrogates of cardiovascular disease, such as waist-to-hip ratio, lipids, and markers of inflammation, as well as primary cardiovascular disease outcomes such as death and events in both observational and randomized controlled trial data. These enhancements easily rival those seen with more established tools used to fight cardiovascular disease such as aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, and exercise. However, it is unclear if the Mediterranean diet offers cardiovascular disease benefit from its individual constituents or in aggregate. Furthermore, the potential benefit of the Mediterranean diet or its components is not yet validated by concrete cardiovascular disease endpoints in randomized trials or observational studies. This review will focus on the effects of the whole and parts of the Mediterranean diet with regard to both population-based and experimental data highlighting cardiovascular disease morbidity or mortality and cardiovascular disease surrogates when hard outcomes are not available. Our synthesis will highlight the potential for the Mediterranean diet to act as a key player in cardiovascular disease prevention, and attempt to identify certain aspects of the diet that are particularly beneficial for cardioprotection.

© 2015 Elsevier Inc. All rights reserved.

KEYWORDS: Cardiovascular disease; Mediterranean diet

Cardiovascular disease is the leading cause of morbidity and mortality in the world regardless of race, ethnicity, or sex, and costs related to cardiovascular disease in the United States are expected to surpass $300 billion in 2010.1 Optimistically, simple and cost-effective steps such as a proper diet should be able to alleviate the obesity epidemic and the resultant cardiovascular disease burden, as it is estimated that lifestyle choices can account for up to 40% of premature cardiovascular disease deaths.2 Consistently, the Mediterranean diet—consisting of fish, unsaturated fats, whole grains, fruits and vegetables, nuts and legumes—has consistently been shown to reduce cardiovascular morbidity and mortality as well as surrogate markers in meta-analyses, cohort studies, and randomized control trials (RCTs). These improvements match reductions in cardiovascular disease burden demonstrated by highly proven and advertised interventions, and approach measures such as physical activity and smoking cessation (Figure 1).3-16 This historical and narrative review examines current professional society guidelines, RCTs, observational studies, and meta-analyses throughout the literature pertaining to the Mediterranean diet—and the components thereof—dating back to the inception of such a concept with the Seven Countries Study17 in the 1980s in an effort to critically examine the
role of the Mediterranean diet and its components in ameliorating the burden of cardiovascular disease.

THE MEDITERRANEAN DIET, IN TOTO

The authors of the Seven Countries Study note that in contrast to the rest of the developed world, the farmers of Crete consumed some of the largest amounts of fat, yet had the lowest cardiovascular mortality rate. The diet does not single out specific food items or limit calories, but rather emphasizes an abundance of plant foods, olive oil as the principal source of fat, limited dairy products, consumption of moderate amounts of fish, poultry, and wine, low amounts of red meat, and fresh fruit daily—consistent with current American Heart Association (AHA) and European Society of Cardiology (ESC) recommendations for dietary caloric distribution.

Principal in the data favoring the Mediterranean diet is the Lyon Heart Study, which showed in an RCT that composite endpoints of cardiovascular disease events and death were reduced for up to 4 years after an initial event in those randomized to the Mediterranean diet, thus establishing it as a staple in secondary prevention. Recently, the PREvencion con Dieta Mediterranea (PREDIMED) investigators completed an RCT comparing a low-fat diet to the Mediterranean diet supplemented with either olive oil or nuts. This trial was, in fact, halted early after a significant reduction in cardiovascular disease events was overwhelmingly evident in the Mediterranean diet arms of the trial, and distinctly marked almost immediately after randomization. This flagship study is one of the largest randomized trials focusing on primary cardiovascular disease prevention, and clearly places the Mediterranean diet at the forefront of preventative cardiovascular medicine. More copious, yet congruent, observational and RCT data exist, with one RCT evaluating surrogate markers of cardiovascular disease prevention showing that the Mediterranean diet reduces the risk of repeat cardiovascular events. Further RCT evidence supports the use of a Mediterranean diet to reduce genetic predisposition for risk factors, not cardiovascular disease morbidity or mortality and their complications, in a high-risk population. This trial (a sub-study of the multicenter PREDIMED study) shows that patients on the Mediterranean diet had fewer monocytes, inflammatory markers, and beneficial modulation of gene expression involved in low-density lipoprotein (LDL) oxidation. The Mediterranean diet seems to show beneficial effects regarding the metabolic syndrome and diabetes compared with low-fat diets, especially when enriched with either nuts or olive oil.

Observational and ecological studies such as the original Seven Countries Study have shown positive benefits of the Mediterranean diet in terms of cardioprotection, surrogate markers for cardiovascular disease, as well as overall morbidity and mortality. Subsequently, a large meta-analysis of over 50,000 patients showed that the Mediterranean diet significantly reduced the risk of metabolic syndrome and protected against risk factors such as waist circumference, lipids, glucose, and blood pressure in primary prevention (Figure 2). Another meta-analysis of 2650 patients showed that the Mediterranean diet provided a more robust reduction in cardiovascular disease risk factors and inflammatory markers.

In fact, the Mediterranean diet is comparable with other interventions such as aspirin, statins, physical activity, and even antihypertensives such as angiotensin-converting enzyme inhibitors or beta-blockers in terms of reducing the risk of cardiovascular disease morbidity, mortality, and events (Figure 1). These estimates, of course, are rough due to the vast heterogeneity in the types and varieties of studies and their sizes, subjects, styles, and primary/secondary endpoints. Consequently, the data about the Mediterranean diet for cardiovascular disease morbidity and mortality reduction is robust, and recently cemented by a primary prevention RCT showing overwhelming benefit.

The remainder of this review will examine the foods that comprise the Mediterranean diet in an effort to review the observational vs RCT data of the individual components of the diet, which may offer insights into which foods within the diet might offer a reduction in cardiovascular disease morbidity and mortality.

CLINICAL SIGNIFICANCE

• The Mediterranean Diet has been proven by randomized controlled trials, observational studies, and meta-analyses to be beneficial for both primary and secondary prevention of cardiovascular disease.

• No specific component of the Mediterranean diet has been shown to be as beneficial as the whole.

• Calorically mindful portions of each individual component should be recommended to patients for cardiovascular prevention. Further study is required to understand the contribution of the constituents of the Mediterranean diet.

OMEGA-3 POLYUNSATURATED FATS, SUCH AS FISH

The marine omega-3 fatty acids are polyunsaturated fatty acids and widely studied in the Mediterranean diet. Per recommendations made by the AHA/American College of Cardiology (ACC), fish should be consumed twice per week in cases of known cardiovascular disease. European guidelines endorse the isocaloric consumption of fish for primary and secondary cardiovascular disease and possibly dysrhythmia protection.

A multitude of meta-analyses have shown a potential cardiovascular disease morbidity and mortality benefit for
mainly secondary prevention with increased fish intake.\textsuperscript{33-42} A systematic review of RCTs has shown that marine omega-3 portends a benefit for cardiovascular disease risk reduction (relative risk = 0.57),\textsuperscript{43} and has been confirmed by numerous RCTs, with the principal sources for these data the Diet and Reinforcement Trial (DART), Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevention, and Japan EPA Lipid Intervention Study (JELIS) studies.\textsuperscript{44-47} Recent meta-analyses of observational studies support the intake of higher amounts of fish (40-60 grams/day or 1-2 times/week) in high-risk populations.\textsuperscript{41,48,49} Although less convincing, primary prevention data are favorable as long as patients carefully balance fish intake to 2-3 times/week to minimize the risk of mercury toxicity. A primary drawback in these larger meta-analyses is heterogeneity in fish intake vs fish oil supplementation in the comparisons. Certainly RCTs examining fish oil supplementation in patients already on maximal medical therapy have shown a reduced effect on cardiovascular disease outcomes.\textsuperscript{47} The well-controlled confounders in fish oil supplementation RCTs may be a source of discrepancies between these studies and larger, positive observational trials.

One of the largest cohort trials examining fish intake and cardiovascular disease, the Physician’s Health Study published in 1995, utilized prospective cohort data to argue against an association between fish consumption and cardiovascular disease benefit.\textsuperscript{50} These data were then confirmed that same year by a larger cohort of health professionals that showed no association between increased fish consumption (from 1-2 to 5-6 servings/week) and reduced cardiovascular disease mortality.\textsuperscript{51} As these are observational studies, selection bias and recall bias must be taken into consideration when evaluating these data in relation to the entire body of work, as meta-analyses of prior observational data support the cardiovascular benefits of fish in moderate- to high-risk cardiovascular disease patients.

Mechanisms underlying the beneficial effects of fish on cardiovascular disease include improved lipid profiles\textsuperscript{52} and reduced blood pressure,\textsuperscript{53,54} presumably through reduced inflammation, oxidation, and coagulation (Figure 2).\textsuperscript{55,56} Thus, diets with moderate fish intake seem to confer

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{Figure1.png}
\caption{Estimates of risk ratio reduction based on recent meta-analyses of trials examining medication adherence vs placebo and lifestyle interventions vs control. Estimates on the effect of niacin were removed as there are no recent meta-analyses that include recent negative data. Relative risks are reported with logarithmic conversions and standard errors plotted on the Forest plot. Estimates of lifestyle modifications such as the Mediterranean diet as a whole,\textsuperscript{12} fruits and vegetables,\textsuperscript{3-5} smoking cessation,\textsuperscript{9} moderate alcohol,\textsuperscript{11} omega-3 fatty acids,\textsuperscript{16} and improved physical activity\textsuperscript{3} have substantial benefits for CVD prevention not seen with commonly used standard medical therapies such as statins,\textsuperscript{6,7} renin-angiotensin system blockade,\textsuperscript{10} fibrates,\textsuperscript{13} aspirin,\textsuperscript{14} and beta-blockers.\textsuperscript{15}}
\end{figure}
cardiovascular disease benefits—indeed, independent of their presence within the Mediterranean diet—and should comprise a key culinary component for patients seeking a heart-healthy diet either independently or in conjunction with the remainder of the Mediterranean diet.

**UNSATURATED FATS, SUCH AS OLIVE OIL**

One of the most prominent aspects of the Mediterranean diet is the high concentration of unsaturated fats in its sources of fiber and protein, coupled with a paucity of saturated fats. Both the AHA/ACC and ESC guidelines strongly endorse substituting mono- and polyunsaturated fats in place of saturated and trans-fatty acids for both primary and secondary prevention.

Research on the impact of olive oil consumption for cardiovascular disease prevention has expanded over the last decades. Currently, hard cardiovascular disease endpoints, however, are lacking from the data in the form of RCTs. Instead, interest lies mainly in the mechanisms behind the minor polar compounds with potent antioxidant properties, including simple and complex phenols, which are present in appreciable amounts in extra virgin olive oils. Now, the cardioprotective effects of olive oil are thought to be attributed to the presence of its phenolic compounds obtained from the water-soluble fraction and include mostly the low-molecular-weight molecule hydroxytyrosol and also oleuropein, which are both potent antioxidants, free radical scavengers, and enzyme modulators. Two randomized, blinded crossover trials have assessed the antioxidant effect of dietary supplementation of extra virgin olive oil in humans: EUROLIVE and the Virgin Olive Oil Study (VOLOS). The Italian VOLOS trial studied the inflammatory protective potential of olive oil in 22 mildly dyslipidemic patients. After a 7-week treatment period, levels of thromboxane B2 (an index of maximal platelet activation) and total antioxidant capacity of plasma were both reduced with administration of olive oil without change in overall serum lipid profiles. In the Effect of Olive Oil on Oxidative Damage in European Populations (EUROLIVE) study, a randomized, crossover controlled trial performed at 6 research centers across 5 European studies, patients received olive oil with low, medium, or high phenolic content for 3 weeks, with intervening 2-week washout periods. There was a linear decrease in markers of oxidative stress with increasing phenolic content by 1.21 to 3.21 U/L. A recent randomized crossover trial in a small group of healthy patients demonstrated that not only does the Mediterranean Diet (rich with olive oil) improve endothelial function and reduce systemic inflammation, but it also improves endothelial progenitor cell numbers, which the authors report as a marker of increased endothelial repair. Ex vivo observations in healthy volunteers showed that, in contrast to butter- and walnut-rich meals, consumption of an olive oil-rich meal does not induce the postprandial activation of nuclear factor-kB pathway in monocytes, thus suggesting an anti-inflammatory effect. Recent data from our laboratory indicate a beneficial effect of olive oil supplementation on endothelial function in low- to moderate-risk patients.

Early meta-analyses primarily evaluating the effects of fatty acids on surrogate markers for cardiovascular disease, such as cholesterol, indicated that monounsaturated fatty
acid intake increased lipid levels, including high-density lipoprotein. Scant evidence establishes the effect of monounsaturated fats alone on cardiovascular disease mortality, yet a large meta-analysis suggests an inverse correlation between blood pressure and monounsaturated fats intake. Finally, there are RCT data that the Mediterranean diet supplemented with olive oil proffers cardiovascular disease surrogate and morbidity benefit, respectively. However, teasing apart olive oil as being of primary benefit in these trials is difficult to do, as nut supplementation showed similar results in primary outcomes.

**FRUITS AND VEGETABLES**

Nearly every diet—including the Mediterranean—aimed at improving cardiovascular health encourages daily intake of multiple servings of both fruits and vegetables. In fact, the ESC strongly endorses the dietary use of fruits and vegetables to reduce cardiovascular disease risk, and the AHA has twice re-affirmed a similar stance. Additionally, the AHA has strongly recommended the intake of a variety of phytochemicals, of which fruits and vegetables have large quantities, for the prevention of cardiovascular disease. These recommendations are based upon a broad base of observational studies, and subsequent meta-analyses, with sparing support from RCT data, pointing to potential benefits of increased fruit and vegetable intake.

Copious observational data show a reduction in cardiovascular disease surrogates by individuals who report increased consumption of fruits and vegetables. A 2003 study showed a 3.0-mm Hg decrease in systolic blood pressure among women who consumed a higher amount of fruits, vegetables, or vitamin C, with no difference in men. A 2004 cross-sectional analysis of a prospective cohort study (the SUN study) showed that fruit and vegetable consumption is inversely associated with blood pressure in a Mediterranean population with a high vegetable-fat intake. Increased fruit and vegetable intake has also been linked with a lower body mass index (BMI) in another cross-sectional study. Finally, the prospective Chicago Western Electric Study showed a slight benefit on blood pressure compared with intake of red meat over a 7-year period of time. This body of work demonstrates that increased red meat consumption produced a net blood pressure elevation in middle-aged men compared with an increased fruit and vegetable intake.

A large 2006 meta-analysis of nearly 200,000 patients showed a 4% relative risk reduction in cardiovascular disease with each serving of vegetables, with a 7% relative risk reduction in cardiovascular disease with each daily increase in servings of fruit, although the results were slightly skewed by heterogeneity and publication bias. Another large (over 200,000 patients) meta-analysis of observational studies showed a 17% reduction in cardiovascular disease events with 3-5 servings of fruits and vegetables daily as the primary endpoint, data that were reaffirmed 2 years later. Recently, population-based evidence from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Heart study showed, after an 8-year follow up of 313,074 patients without overt atherosclerosis, a 22% lower risk of fatal ischemic heart disease in those consuming 8 portions of fruits and vegetables a day, as compared with 3 portions or less.

RCT data are not as convincing, and only peripherally address the cardiovascular disease benefits of fruits and vegetables by utilizing cardiovascular disease surrogates as endpoints. A 2001 RCT showed that increased fruits and vegetables portended no significant change in lipid or blood pressure profiles, although a strong trend existed for both. A subsequent RCT showed a statistically significant effect of fruit and vegetable consumption on both plasma antioxidant concentrations and blood pressure. Interestingly, the potential benefit of fruits and vegetables could lie in reduced total caloric burden, or in the numerous micronutrients that they provide. While solid evidence establishes the antioxidant properties of fruit and vegetables and the health benefits of increased flavonol intake, alternative mechanisms have been proposed and could include the effects of nitric oxide (NO) species or concomitant weight loss associated with diets high in fruits and vegetables. Although a wide array of RCT, outcomes-based data do not, to our knowledge, exist in the literature, we support the use of fruits and vegetables for cardiovascular disease prevention. However, this may be a case whereupon the synergistic effects of fruits and vegetables along with the remainder of the Mediterranean diet, although not yet tested, provide the most cardiovascular disease benefit.

**WHOLE GRAIN FOODS HIGH IN FIBER**

Many data suggest a beneficial effect of increased whole grains on cardiovascular disease morbidity and mortality. The AHA guidelines indicate that diets high in fiber such as whole grains, oats, and barley, reduce cardiovascular disease morbidity and mortality through lipid lowering, and recommend a total dietary fiber intake of 25-30 g per day from whole foods. While the ESC does not have specific guidelines or recommendations about the purpose or amount of whole grains consumption, it endorses intake of foods high in dietary fiber to promote cardiovascular disease health.

RCTs show mixed data on surrogate markers of cardiovascular disease such as blood pressure, cholesterol, and markers of inflammation; however, there is no overt information about hard cardiovascular disease endpoints. A smaller RCT showed beneficial effects on BMI and waist circumference in the group randomized to hypocaloric whole grains as opposed to hypocaloric refined grains. Moreover, the group obtaining all carbohydrates from whole grains for 12 weeks had significant improvements in C-reactive protein levels and cholesterol profile. A larger, subsequent, RCT confirmed these results in over 230 participants randomized to 3 daily servings of refined carbohydrates vs whole grains ± whole oats, with the latter showing significant improvements in blood pressure and
lipid profiles. In a recent RCT, over 300 overweight individuals were randomized to control, intermediate whole grain, or high whole grain diets for 4 months in substitution for their normal carbohydrate intake. No significant differences in cardiovascular disease surrogate markers were observed after 4 months, although the study might have been underpowered to detect them in such a short period of time, despite a similar design to the positive trials involving whole grains and cardiovascular disease.

A single meta-analysis evaluating the merit of whole grains showed a collective benefit in a series of prospective cohort studies, with a 21% reduction in cardiovascular disease events and mortality. Larger observational studies have shown a reduction in cardiovascular disease morbidity with increased intake of whole grain sources in the Iowa Women’s Study and the Nurses Health Study. Finally, observational data show improved all-cause and cardiovascular disease mortality in women with type 2 diabetes who consume whole grains.

Mechanisms for the benefit of whole grains on cardiovascular disease are numerous, but the whole-body benefits of increased fiber from whole grains appear to be related to reduced inflammation, reactive oxidation, lipid profiles, and blood pressure. Observational studies show that benefits extend to improved glucose metabolism, reduction in weight, and antioxidant capabilities. Alternatively, high-fiber whole grain diets could inhibit absorption of fats, simple carbohydrates, or toxins. Nevertheless, the benefit of increased fiber intake has been confirmed by large cohort studies and meta-analyses, yet the recommendation promoting whole grains has no RCT data about a reduction in cardiovascular disease morbidity or mortality behind it. As such, increased whole grain intake should still be pursued for cardiovascular disease prevention, however, its isolation from the remainder of the Mediterranean diet might not maximize its true cardioprotective potential.

NUTS AND LEGUMES
Predominantly, the data about the beneficial effect of moderate nut consumption are positive, yet similar convincing evidence cannot support the same for legumes. Few meta-analyses or RCTs describe the cardiovascular disease morbidity and mortality impact of nuts, but most early observational data point to a reduction in cardiovascular disease risk with isocaloric nut consumption as a major source of fat. One recent analysis predicted that nut consumption could offer a 0.67 preventative risk reduction on heart disease. One early evaluation of observational studies showed that substituting walnuts, peanuts, almonds, or other nuts for a serving of carbohydrates or saturated fats reduced blood lipids as well as the risk for cardiovascular disease by 30% and 45%, respectively.

Furthermore, a recent 2009 meta-analysis showed a significant reduction in LDL cholesterol, inflammatory and oxidants mediators with increased walnut consumption, but no evidence established meaningful reductions in other risk factors or cardiovascular disease mortality. Interestingly, a more recent meta-analysis pointed out benefits of nuts on weight loss. One of the largest studies published in 2006, a meta-analysis of 4 observational studies (Adventist Health Study, Iowa Women’s Health Study, Nurses’ Health Study, and the Physician’s Health Study), showed an inverse relationship between nut consumption and cardiovascular disease (primary endpoint), with a nearly 40% decrease in the incidence of primary cardiovascular disease with consumption of at least 4 nut servings per week and up to 10% reduction with a single serving per week.

RCT data, again, is less convincing, likely secondary to underpowered studies and the large variety of nuts that could be studied. However, recent RCT data mentioned early in the review offer evidence that the Mediterranean diet supplemented with nuts offers primary cardiovascular disease-prevention benefits. Again, these benefits were seen in conjunction with the remainder of the Mediterranean diet, so ascribing the benefit solely to nuts would be an overstatement of the data. Numerous cohort studies and quite a few smaller RCTs have shown a benefit in terms of lipid profiles, reducing ROS, improving vascular function, reducing blood pressure, and improving cardiovascular morbidity and mortality. Furthermore, such convincing evidence about increased nut consumption on cardiovascular disease prevention would likely lend it to being a food that can be consumed in isolation, without the added benefit offered by the Mediterranean diet, although when added to the Mediterranean diet, can offer greater cardiovascular disease benefit.

Conversely, the data about other legumes are not as positive. Legumes are typically considered the seeds of plants that contain roots, which utilize nitrogen-fixing bacteria on their roots, comprised of a wide variety of sources and types difficult to carefully study. These seeds are considered low-glycemic and a useful dietary source of protein and fiber. Initial observational studies showed legume and soy intake to be beneficial toward preventing cardiovascular disease, as National Health and Nutrition Examination Survey data showed an 11% reduction in cardiovascular disease in women who consumed legumes 4 or more times weekly over those who consumed legumes one, or fewer, time weekly. Similar observational data have been reported out of Japan and China.

RCT data rarely address hard cardiovascular disease endpoints, and the grouped data show only marginal benefits with regard to lipid levels, blood pressure, or endothelial function. Small RCTs in low- to moderate-risk patients show little to no change in lipid levels. Yet one meta-analysis shows a 5% reduction in LDL levels in patients who were randomized to high legume intake, however, this reduction was not noted to have an effect on hard cardiovascular disease endpoints. RCTs have shown a benefit on blood pressure in patients with moderate hypertension and a recent RCT shows no benefit of soy on NO bioavailability or BP in moderately hypertensive,
postmenopausal women,\textsuperscript{106} consistent with prior meta-analyses mentioned above.\textsuperscript{104}

However, subsequent meta-analyses have been less convincing about cardiovascular disease benefit, particularly with regard to surrogate endpoints. Due to a potential anti-inflammatory and vasoprotective benefit, a multitude of studies has examined the effect of soy on endothelial function. A fairly recent meta-analysis of RCTs shows no benefit of soy on endothelial function\textsuperscript{107}; however, when the age-related results are adjusted for baseline endothelial function, there is a moderate benefit of soy supplementation. A larger sample of RCTs studies showed no benefit from soy supplementation on normotensive patients,\textsuperscript{108} and an earlier meta-analysis mirrored these findings.\textsuperscript{109} Thus, despite an abundance of observational data, and recent, well-designed RCTs and subsequent meta-analyses, we find little direct evidence that legume intake alone has direct cardiovascular disease benefit. Interestingly, while nutritionally similar and usually grouped together with nuts—which do have a positive cardiovascular disease impact—it could be hypothesized that legume intake must be part of the Mediterranean diet as a whole, and cannot be supplemented in isolation for cardiovascular disease protection.

**CONCLUSIONS**

The Mediterranean diet is arguably the best-studied and most evidence-based diet to prevent not only cardiovascular disease, but also other chronic diseases, as it has become the standard for healthy eating and a dietary template of particular value. The primary advantage of the Mediterranean diet appears to lie in its synergy among various cardioprotective nutrients and foods.\textsuperscript{110} Indeed, the diet and, to a lesser degree, its components, have been found to reduce cardiovascular disease risk by mechanisms including reduction of surrogates of cardiovascular disease such as blood pressure, lipids, endothelial dysfunction, glucose, BMI, and waist circumference, as well as by providing increased NO bioavailability, antioxidant properties, and anti-inflammatory effects (Figure 2).

As illustrated in this review, the Mediterranean diet has proven secondary cardiovascular disease prevention benefit and improvements in surrogate markers for cardiovascular disease as evidenced by copious observational, RTC, and even meta-analyses. Certain constituents of the Mediterranean diet, including fish and nuts, have established cardiovascular morbidity/mortality benefits (Table), which can possibly be noted in isolation from the remainder of the Mediterranean diet. Both observational and RCT data documented improvement in cardiovascular disease prevention (Table) with constituents of the Mediterranean diet, which should be consumed in moderation to ensure a balanced diet and avoid caloric excess. Preventive measures depend strongly upon length of time followed—it is a life-long commitment, not something that can be done episodically. Duration may be more important than intensity, especially because high intensities are difficult to sustain. Simply changing one or following a few dietary constituents does not exclude detrimental effects of the rest of the diet or lifestyle. This is, of course, why the dietary pattern is much more important than the effects of individual constituents. In fact, the content of this review reveals that our best culinary interventions may not involve specific foods, but relate to a collection of healthy nutrients comparable with the Mediterranean diet—that is comprised of a group of foods considered beneficial for cardiovascular health.

**References**


Widmer et al. The Mediterranean Diet and Cardiovascular Disease 237


